Flash glucose-sensing technology shown to reduce hypoglycaemia
Flash glucose-sensing technology used for glycemic management in those with type 2 diabetes on insulin can help reduce hypoglycaemia, new research has shown.
The open-label, randomised, controlled study also showed that the technology could also “safely and effectively” replace self-monitoring of blood glucose (SMBG).
The research took place across 26 European diabetes centres on adults with type 2 diabetes on intensive insulin therapy. The researchers wanted to assess how flash glucose sensing technology compared wth SMBG.
The participants were divided up into two groups which compiled of one group using the FreeStyle Lite SMBG and the other using the FreeStyle Libre flash glucose monitoring system across six months initially. All intervention group participants who completed the first six-month treatment phase continued into an additional six-month open-access phase.
At 12 months, time in hypoglycemia [sensor glucose <3.9 mmol/L (70 mg/dL)] was reduced by 50 per cent compared to baseline [−0.70 ± 1.85/24 h (mean ± standard deviation); p = 0.0002].
Nocturnal hypoglycemia [2300 to 0600 hours, <3.9 mmol/L (70 mg/dL)] was reduced by 52 per cent; p = 0.0002. There was no change in time in range [sensor glucose 3.9–10.0 mmol/L (70–180 mg/dL)]. SMBG testing fell from a mean of 3.9 (median 3.9) times/day at baseline to 0.2 (0.0), with an average frequency of sensor scanning of 7.1 (5.7) times/day at 12 months, and mean sensor utilisation was 83.6 ± 13.8 per cent (median 88.3 per cent) during the open-access phase.
During this six-month extension period no device-related serious adverse events were reported. Nine participants reported 16 instances of device-related adverse events (e.g. infection, allergy) and 28 participants (20.1 per cent) experienced 134 occurrences of anticipated skin symptoms/sensor-insertion events expected with device use (e.g. erythema, itching and rash).